Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation

Share-based compensation

3 Months Ended

Mar. 31, 2017

Note 9 — Share-based compensation

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (thousands):

	Three months ended March 31,
	2017		2016

Research and development	$	1,359	$	893
General and administrative	1,327		1,181

	$	2,686	$	2,074

There were 18,950,976 and 13,575,554 options over ordinary shares granted in the three months ended March 31, 2017 and 2016, respectively. The weighted average fair value of stock options granted in the three months ended March 31, 2017 and March 31, 2016 was $0.34 and $0.89, respectively.

At March 31, 2017, there were 3,224,600 share options granted to nonemployees outstanding. The total share based compensation relating to these options was an expense of $205,000 and a benefit of $314,000 in the three months ended March 31, 2017 and 2016, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details